e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 16, 2009
Ardea Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
1-33734
|
|
94-3200380 |
|
|
|
|
|
|
| (State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer |
| of incorporation)
|
|
File Number)
|
|
Identification No.) |
| |
|
|
| 4939 Directors Place
|
|
92121 |
| San Diego, California
|
|
(Zip Code) |
| (Address of principal executive offices) |
|
|
Registrant’s telephone number, including area code: (858) 652-6500
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
| Item 7.01. |
|
Regulation FD Disclosure. |
A copy of presentation materials describing the business of Ardea Biosciences, Inc. (the “Company”)
to be used by the Company from time to time is filed as Exhibit 99.1 hereto. These materials
include updates to information previously furnished by the Company regarding the Company’s research
and development programs, including information relating to expected research and development
milestones. The Company does not intend to file any update of these presentation materials in the
future. The fact that these updated presentation materials are being furnished should not be
deemed an admission as to the materiality of any information contained in the materials.
The Company also recently announced the scheduling of an investor and
analyst event to be held on April 20, 2009 from 4:30 p.m. to 7:00
p.m. Eastern Daylight Time in New York City. A copy of the related
press release is filed as Exhibit 99.2 to this Form 8-K and is
incorporated herein by reference in its entirety.
The
information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth
by specific reference in such filing.
|
|
|
| Item 9.01 |
|
Financial Statements and Exhibits. |
(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:
| |
|
|
| Exhibit Number |
|
Document Description |
|
|
|
99.1
|
|
Ardea Biosciences, Inc. presentation materials updated as
of March 16, 2009, and to be used from time to time
thereafter. |
| |
99.2
|
|
Press Release Dated March 16, 2009. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
|
|
|
|
| |
ARDEA BIOSCIENCES, INC.
|
|
| Date: March 16, 2009 |
/s/ John W. Beck
|
|
| |
John W. Beck |
|
| |
Chief Financial Officer |
|
| |
EXHIBIT LIST
| |
|
|
| Exhibit Number |
|
Document Description |
|
|
|
99.1
|
|
Ardea Biosciences, Inc. presentation materials updated as
of March 16, 2009, and to be used from time to time
thereafter. |
| |
99.2
|
|
Press Release Dated March 16, 2009. |